Clinical trial Recruiting at 1 site Phase 3 Interventional Ages Any age to 32 Weeks

Dexmedetomidine versus Midazolam to shorten time on the ventilator in very preterm infants

Official title: Efficacy of Dexmedetomidine Versus Midazolam Sedation on Extubation Time in Mechanically Ventilated Preterm Infants: a Randomized Controlled Multicenter Trial - DEXPRE

Run by Assistance Publique - Hôpitaux de Paris · NCT06878703 · Data updated 2026-11-12

This trial will test whether using dexmedetomidine instead of midazolam helps very preterm infants on invasive mechanical ventilation be extubated sooner.

More PreTerm Neonate trials

Quick facts

PhasePhase 3
Study typeInterventional
AgesAny age to 32 Weeks
SexAll
Enrollment380 (estimated)
SponsorAssistance Publique - Hôpitaux de Paris
Academic / other
Locations1 site (Paris)
StatusRecruiting
StartedOctober 16, 2025
Main results expectedDecember 30, 2027
Study endsOctober 16, 2029
Registry record updatedFebruary 10, 2026
Trial IDNCT06878703 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Very preterm neonates born before 32 weeks' gestation with corrected age under 45 weeks who require sedation for invasive mechanical ventilation and whose parents provide informed consent.

Probably not a fit

Infants with hemodynamic instability, recent extubation, receiving contraindicated medications (e.g., clonidine or curare), or other contraindications to dexmedetomidine or midazolam are unlikely to benefit or be eligible.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This randomized phase 3 trial compares continuous intravenous dexmedetomidine infusion versus continuous intravenous midazolam infusion for sedation of very preterm neonates (<32 weeks gestation) who require invasive mechanical ventilation. Infants are randomized to receive a loading dose followed by a maintenance infusion within specified dose ranges for each drug while on ventilation, with care delivered in participating NICUs. The primary outcome centers on time to successful extubation and the protocol aims to enroll about 292 randomized patients (anticipating ~380 screened). Standard inclusion/exclusion and safety monitoring procedures are used to limit enrollment to clinically stable infants without contraindications to either agent.

Why it matters

Potential benefit: If successful, the dexmedetomidine arm could shorten duration of invasive ventilation and help reduce lung injury and rates of bronchopulmonary dysplasia by enabling earlier extubation.

How similar studies have gone: Small randomized and observational studies suggest dexmedetomidine is feasible and may cause less respiratory depression than benzodiazepines, but definitive phase 3 evidence in very preterm infants is limited.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Patient admitted in NICU (intubated or not yet),
* Gestational age at birth \< 32 weeks of gestation (WG),
* Corrected gestational age \<45 weeks postmenstrual age Written or electronic informed consent signed by both parents.

Randomization Criteria :

* Indication for sedation in the context of invasive mechanical ventilation,
* Patient intubated or not yet,
* Elective sedation (acceptable delay between the decision to sedate and the administration of the sedative agent),
* Presence or plan of a venous access,
* No medical contraindication related to the administration of dexmedetomidine or midazolam,
* No previous use of dexmedetomidine or midazolam within 48 hours, except for the sedation procedure for intubation,
* No concomitant use of curare agent,
* No clonidine treatment,
* No previous extubation within 7 days,
* No hemodynamic instability
* No palliative care,

Exclusion Criteria:

* Patient admitted in NICU (intubated or not yet),
* Gestational age at birth \< 32 weeks of gestation (WG),
* Corrected gestational age \<45 weeks postmenstrual age Written or electronic informed consent signed by both parents.

Where it's running

  • Hospital Armand Trousseau, APHP Service : Department of Neonatology
    Paris, France
    Recruiting

Study contacts

  • Principal investigator: Clément CHOLLAT, Doctor — Assistance Publique - Hôpitaux de Paris
  • Study coordinator: Clément CHOLLAT, MD, PhD, Associate Professor
  • Email: clement.chollat@aphp.fr
  • Phone: +33 6 86 72 29 58

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.